ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 180 filers reported holding ASCENDIS PHARMA A/S in Q1 2021. The put-call ratio across all filers is 1.02 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $26,773,362 | +3.5% | 285,918 | -1.4% | 3.32% | +9.8% |
| Q2 2023 | $25,870,005 | +0.9% | 289,860 | +21.3% | 3.02% | -1.8% |
| Q1 2023 | $25,629,654 | -12.1% | 239,038 | +0.2% | 3.08% | -20.6% |
| Q4 2022 | $29,142,783 | +24.1% | 238,621 | +4.9% | 3.88% | +20.1% |
| Q3 2022 | $23,484,000 | +61.0% | 227,427 | +45.0% | 3.23% | +62.0% |
| Q2 2022 | $14,585,000 | -10.0% | 156,900 | +13.7% | 1.99% | +27.6% |
| Q1 2022 | $16,199,000 | -13.8% | 138,030 | -1.2% | 1.56% | -9.5% |
| Q4 2021 | $18,790,000 | -2.4% | 139,673 | +15.6% | 1.73% | -10.4% |
| Q3 2021 | $19,256,000 | +92.0% | 120,810 | +58.4% | 1.93% | +88.6% |
| Q2 2021 | $10,031,000 | +3.7% | 76,252 | +1.6% | 1.02% | -9.1% |
| Q1 2021 | $9,675,000 | -1.9% | 75,068 | +26.9% | 1.12% | -7.4% |
| Q4 2020 | $9,863,000 | +46.4% | 59,136 | +35.4% | 1.21% | +14.6% |
| Q3 2020 | $6,739,000 | +49.1% | 43,669 | +42.8% | 1.06% | +24.4% |
| Q2 2020 | $4,521,000 | +30.6% | 30,571 | -0.6% | 0.85% | +1.8% |
| Q1 2020 | $3,463,000 | +65.1% | 30,748 | +103.9% | 0.84% | +136.8% |
| Q4 2019 | $2,098,000 | – | 15,079 | – | 0.35% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |